Ficerafusp Alfa

Merus announced that 79% of patients with newly diagnosed metastatic head and neck cancer survived at least one year when treated with petosemtamab in combination with Keytruda.

Cidara Therapeutics has completed enrollment of 5,000 subjects in its Phase 2b NAVIGATE trial evaluating CD388, a single-dose universal influenza preventative drug.

Bicara Therapeutics initiates FORTIFI-HN01, a global Phase 2/3 trial evaluating ficerafusp alfa combined with pembrolizumab in first-line recurrent/metastatic head and neck squamous cell carcinoma.

Clinical trial results presented at ASCO GI demonstrate improved objective response rate and progression-free survival when combining ficerafusp alfa with Keytruda in EGFR+ anal cancer patients.

Bicara Therapeutics has presented new Phase 1/1b data for ficerafusp alfa, a novel bifunctional antibody targeting both EGFR and TGF-beta, in combination with pembrolizumab for advanced anal cancer treatment.